CTI BIOPHARMA
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
CTI BIOPHARMA
Industry:
Biotechnology Health Care Therapeutics
Founded:
1991-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.ctibiopharma.com
Total Employee:
251+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
185.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Agile Therapeutics
Agile Therapeutics is pharmaceutical company developing contraceptive healthcare products for women.
Calithera Biosciences
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Epizyme
Epizyme is a biopharmaceutical company focusing on treatments for blood cancer and tumors.
Galera Therapeutics
Galera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
DRI Healthcare Trust
DRI Healthcare Trust investment in Post-IPO Debt - CTI BioPharma
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - CTI BioPharma
Hercules Capital
Hercules Capital investment in Post-IPO Debt - CTI BioPharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-02-10 | Biowatch | CTI BioPharma investment in Grant - Biowatch | 800 K CHF |
Newest Events participated
Official Site Inspections
http://www.ctibiopharma.com Semrush global rank: 1.91 M Semrush visits lastest month: 11.4 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CTI BioPharma"
CTI BioPharma - Crunchbase Company Profile & Funding
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a …See details»
CTI BioPharma Company Profile | Management and Employees List …
Www.ctibiopharma.com CTI BioPharma Profile and History Founded in 1991, CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization …See details»
CTI BioPharma | Compliance & Transparency
CTI is an organization with strong values of responsibility and integrity. Our written standards and policies contain general guidelines for conducting business with the highest standards of …See details»
CTI BioPharma Corp - AnnualReports.com
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood …See details»
SEC Filing | CTI BioPharma Corp.
Incorporation or organization) (I.R.S. Employer. Identification No.) 3101 Western Avenue, Suite 800 . Seattle, Washington 98121 (206) 282-7100 ... charge at www.sec.gov. Copies of certain …See details»
Acquisition of CTI Biopharma - Swedish Orphan Biovitrum
8 Rationale for the transaction: CTI acquisition is a transformational step for Sobi Differentiated asset by clinical data and mode of action in an area of unmet medical need Highly skilled …See details»
CTI BioPharma - LinkedIn
CTI BioPharma | 9,297 followers on LinkedIn. Providing innovative medicines that transform the lives of people with rare and debilitating diseases. | We have merged with Sobi AB creating a ...See details»
CTI BioPharma Corp. (CTIC) Company Profile & Overview - Stock …
Mar 21, 1997 Ticker Symbol: CTIC: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0000891293: CUSIP Number: 12648L601: ISIN …See details»
Sobi completes acquisition of CTI BioPharma Corp. | Nasdaq
Jun 26, 2023 For more information, please visit www.ctibiopharma.com. Sobi. Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare …See details»
Sobi to Acquire CTI BioPharma - Nasdaq
May 10, 2023 For investors:[email protected]. For media: Kelly Sullivan / Tanner Kaufman / Eduardo Rovira Joele Frank, Wilkinson Brimmer Katcher 212-355-4449 ...See details»
CTI BioPharma - PitchBook
CTI BioPharma General Information Description. Operator of a biopharmaceutical company intended to deliver new medicines to patients with blood-related cancers. The company is …See details»
CTI BioPharma Corp. Company Profile - Dun & Bradstreet
Company Description: CTI Biopharma is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. CTI is developing a number of cancer-fighting …See details»
CTI BioPharma - Craft
Jun 23, 2023 CTI BioPharma has 5 employees across 2 locations and $53.95 m in annual revenue in FY 2022. See insights on CTI BioPharma including office locations, competitors, …See details»
CTI BioPharma CEO and Key Executive Team | Craft.co
CTI BioPharma's President, Chief Executive Officer & Interim Chief Medical Officer, Director is Adam R. Craig. Other executives include Bruce J. Seeley, Chief Operating Officer; David H. …See details»
Working At CTI BioPharma: Company Overview and Culture - Zippia
Mar 14, 2024 www.ctibiopharma.com. Organization Type. Public. Social Media. CTI BioPharma focuses on the acquisition, development and commercialization of therapies for blood-related …See details»
Sobi to Acquire CTI BioPharma - PR Newswire
May 10, 2023 Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023. SEATTLE, May 10, 2023 /PRNewswire/ -- CTI …See details»
Diversity & Inclusion - CTI Website - ctibiopharma.com
CTI is committed to attracting, hiring, retaining and rewarding a diverse workforce. We have prioritized building a culture that fosters understanding, respect and appreciation for diverse …See details»
CTI BioPharma Corp. (CTIC) Stock Price, Quote & News - Stock …
Jun 23, 2023 Website https://www.ctibiopharma.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 6 analysts, the average …See details»
FDA approves CTI BioPharma's bone marrow cancer drug
Mar 1, 2022 CTI BioPharma Corp said on Monday the U.S. Food and Drug Administration had approved its drug for treating adult patients with a type of bone marrow cancer who also have …See details»
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ …
Mar 1, 2022 SEATTLE, Feb. 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO …See details»